On 1-2 March 2022, c4c hosted a successful 2nd online c4c Multi-Stakeholder Meeting on paediatric Atopic Dermatitis (AD). Many thanks to speakers, the Programme Committee and to the 100 participants from academia, regulatory bodies, young patients, advocates and industry representatives. Presentations included biology/immunology of AD in children, perspective from young patients and families and description of industry assets. Over 60 drugs in clinical development or approved were identified. Panel discussions focused on paediatric unmet medical needs and improvement of the evaluation of new medicines for children and adolescents. A scientific manuscript for a specialized journal is currently in development.
More than 100 stakeholders from academia, industry, regulators and patients/patient associations attended our first Multi-Stakeholder Meeting (MSM) on April 14 and 15, 2021. Our first c4c MSM was held online and focused on Paediatric inflammatory Bowel Disease (IBD). There are multiple drugs in development for IBD, however several clinical trials, as part of agreed pediatric development plans, are attempting to enroll patients with limited success. Please find the report on the meeting here